The presence of paroxysmal nocturnal hemoglobinuria in patients with idiopathic chronic renal failure

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal stem cell disease. Chronic renal f ailure (CRF) is defined as progressive deterioration in the regulation of fluid and electrolyte balance of the affected kidney due to a decrease in glomerular filtration rate resulting from various diseases. We also investigated the presence of PNH in foll ow-up patients diagnosed with end-stage renal failure (ESRD) of unknown etiology in this study. This study was carried out at the Yuzuncu Yil University in Van, Turkey. Sixteen patients with end-stage renal failure who had unknown etiology from a total of 143 patients were included in the study. The patients' age, gender, hemogram, biochemical parameters, and percentage of PNH clone were examined. PNH clone was analyzed by the Fluorescein Aerolysin method. Of the patients, 10 (62%) were female, 6 (38%) were male. Hemodialysis was performed in 15 patients (94%) as renal replacement therapy. Fourteen of the patients (88%) had anemia. LDH was elev ated in 6 patients (38%), and those with high LDH also suffered from anemia. PNH clone was negative for all patients as determined by FLAER analysis. A survey of the literature did not result in any study on the presence of paroxysmal nocturnal hemoglobinu ria in idiopathic chronic renal failure. This is the first such study with this focus. Based on review of the cases described in the literature , PNH should be considered in the differential diagnosis of renal failure cases which are unexplained and especia lly those accompanied by hemolysis findings.

Kaynakça

1. Brodsky RA. Narrative review: Paroxysmal nocturnal hemoglobinuria: The physiology of complement-related hemolytic anemia. Ann Intern Med 2008; 148: 587-595.

2. Bessler M, Mason PJ, Hillmen P, et al. Paroxysmal nocturnal hemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. EMBO Journal 1994; 13: 110-117.

3. Hillmen P, Richards SJ. Implications of recent insights into the pathophysiology of paroxysmal nocturnal haemoglobinuria. Br J Haematol 2000; 108: 470-479.

4. Rosse WF. Paroxysmal nocturnal hemoglobinuria as a molecular disease. Medicine (Baltimore) 1997; 76: 63-93.

5. Socié G, Mary JY, de Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: Longterm follow-up and prognostic factors. French Society of Haematology. Lancet 1996; 348: 573- 577.

6. Borowitz MJ, Craig FE, Digiuseppe JA, et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin Cytom 2010; 78: 211-230.

7. Nair RK, Khaira A, Sharma A, Mahajan S, Dinda AK. Spectrum of renal involvement in paroxysmal nocturnal hemoglobinuria: Report of three cases and a brief review of the literature. Int Urol Nephrol 2008; 40: 471-475.

8. Clark DA, Butler SA, Braren V, Hartmann RC, Jenkins DE Jr. The kidneys in paroxysmal nocturnal hemoglobinuria. Blood 1981; 57: 83-89.

9. United States Reanl Data System. Incidence and prevelance of ESRD. Am J Kidney Dis 1998; 32: 38-49.

10. Türk Nefrology Derneği 2015 Registry Raporu (Turkish Society of Nephrology 2015 Registry Report).

11. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333: 1253-1258.

12. Rubin H. Paroxysmal nocturnal hemoglobinuria with renal failure. JAMA 1971; 215: 433-436.

13. Chow KM, Lai FM, Wang AY, Chan YL, Tang NL, Li PK. Reversible renal failure in paroxysmal nocturnal hemoglobinuria. Am J Kidney Dis 2001; 37: 17.

14. Braren V, Butler SA, Hartmann RC, Jenkins DE. Urologic manifestations of paroxysmal nocturnal hemoglobinuria. J Urol 1975; 114: 430-434.

15. Hillmen P, Elebute P, Kelly R, et al. Longterm effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology 2010; 85: 553-559.

16. Umut V, Bahriye P, Mehmet S, Mustafa Y. Chronic Renal Failure Secondary to Paroxismal Nocturnal Hemoglobinuria. International Journal of Hematology and Oncology 2008; 18: 175-179.

17. Sears DA, Anderson PR, Foy AL, Williams HL, Crosby WH. Al Urinary Iron Excretion and Renal Metabolism of Hemoglobin in Hemolytic Diseases. Blood 1966; 28: 708-725.

18. Tomizuka H, Hatake K, Kitagawa S, et al. Portal vein thrombosis in paroxysmal nocturnal haemoglobinuria. Acta Haematol. 1999; 101: 149- 152.

Kaynak Göster

1326 461

Arşiv
Sayıdaki Diğer Makaleler

A young woman with multiple intra cardiac mass, systemic symptoms and stroke

Mohamed Faisal Abdul HAMİD

The Significance of 4D Ultrasonography in Fetal Anomaly Screening

Demet KIRMIZI AYDOĞAN

Emergency cesarean in a patient with atrial septal defect

EROL KARAASLAN

Anesthesia management in a patient with Carney Syndrome: Case report

Abdullah KAHRAMAN, Cahide KAHRAMAN

An unusual bladder mass: Dermoid cyst and review of the literature

Abdullah GÜL, Ahmet ŞAHAN, Canan FIRAT, YILÖREN TANIDIR

Retrospective analysis of patients followed at Van training and research hospital palliative care unit

HAVVA YEŞİL ÇINKIR, Abdullah KAHRAMAN

Contribution of sonoelastography in the differentiation of benign and malignant breast masses: A comparative analysis on sonographic birads classification

HARUN ARSLAN, Zülküf AKDEMİR, Alpaslan YAVUZ, Necat İSLAMOĞLU, SEBAHATTİN ÇELİK, MESUT ÖZGÖKÇE, ABDUSSAMET BATUR, HÜSEYİN AKDENİZ, Harun Egemen TOLUNAY

Survivin expression may affect the neoadjuvant chemotherapy response in breast cancer patients

Zehra ER, HADİCE ELİF PEŞTERELİ, Lema TAVLI, Hakan BOZCUK, GÜLGÜN ERDOĞAN, HACI HASAN ESEN, MEHMET ARTAÇ, LEVENT KORKMAZ, Şeyda GÜNDÜZ, MUSTAFA KARAAĞAÇ, Sinem DEMİRCİOĞLU

Effect of postmenopausal strontium ranelate treatment on oxidative stress in rat skin tissue

MEHMET BERKÖZ, Özgün SAĞIR, SERAP YALIN, ÜLKÜ ÇÖMELEKOĞLU, FATMA SÖĞÜT, Pelin EROĞLU

The comparison of dentin adaptation and sealingability of gutta-percha/AH Plus, Resilon/Epiphany SE,EndoREZ: an in-vitro study

Mert Gökay EROĞLU, Gündüz Şekip BAYIRLI